Status:
TERMINATED
Long-acting Biomedical HIV Prevention in Transgender Women
Lead Sponsor:
University of Colorado, Denver
Collaborating Sponsors:
New York State Psychiatric Institute
Conditions:
HIV Prevention
Transgender Women
Eligibility:
MALE
18-100 years
Phase:
NA
Brief Summary
Transgender women (TW) have unique challenges related to HIV prevention medication adherence. Left unaddressed, these challenges will prevent TW from accessing the promising long-acting HIV prevention...
Eligibility Criteria
Inclusion
- HIV-negative
- self-identified transgender woman (or woman assigned male at birth)
- at least 18 years old
- willing to complete injections
- own a smartphone that uses apps
- speak English or Spanish
- willing to take an HIV test
- live in the NYC/tri-state area
- report receptive or penetrative genital-to-genital sex with another person in the last 3 months
Exclusion
- HIV-positive
- does not identify as a transgender woman (or woman assigned male at birth)
- younger than 18
- unwilling to complete injections
- does not own a smartphone that uses apps
- does not speak English or Spanish
- refuses HIV test
- lives outside of the NYC/tri-state area
- has not had receptive or penetrative genital-to-genital sex with another person in the last 3 months
Key Trial Info
Start Date :
October 23 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2023
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT03856580
Start Date
October 23 2020
End Date
April 30 2023
Last Update
October 4 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York State Psychiatric Institute/Columbia University Medical Center
New York, New York, United States, 10032